Drugs /

ziv-aflibercept

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
ziv-aflibercept
Trade Name(s):
Zaltrap
NCI Definition [1]:
A recombinant protein comprised of epitopes of the extracellular domains of human vascular endothelial growth factor receptors (VEGFR) fused to the constant region (Fc) of human IgG1 with potential antiangiogenic activity. Afilbercept, functioning as a soluble decoy receptor, binds to pro-angiogenic vascular endothelial growth factors (VEGFs), thereby preventing VEGFs from binding to their endogenous receptors. Disruption of the binding of VEGFs to their cellular receptors may result in the inhibition of tumor angiogenesis, metastasis, and ultimately tumor regression.

Clinical Trials

View Clinical Trials for ziv-aflibercept

Ziv-aflibercept has been investigated in 5 clinical trials, of which 5 are open and 0 are closed. Of the trials investigating ziv-aflibercept, 2 are phase 1 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open).

Deficient DNA Mismatch Repair (dMMR), MLH1 Deficient Expression, and MSH2 Deficient Expression are the most frequent biomarker inclusion criteria for ziv-aflibercept clinical trials.

Malignant solid tumor, colorectal adenocarcinoma, and colorectal carcinoma are the most common diseases being investigated in ziv-aflibercept clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ziv-Aflibercept
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ziv-aflibercept and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Zaltrap, ave 0005, aflibercept, vascular endothelial growth factor trap, vascular endothelial growth factor trap, ziv-aflibercept, vegf trap, ziv-aflibercept, vegf trap r1r2, aflibercept, vegf trap - regeneron, aflibercept (product), aflibercept (substance), vegf trap-eye, eylea, eylea, ave0005, aflibercept, ziv-aflibercept, vegf-trap, ave-0005
Drug Categories [2]:
Therapeutic antibodies
Drug Target(s) [2]:
VEGFA, VEGFB
NCIT ID [1]:
C2682
SNOMED ID [1]:
C-F0380

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.